Evidence map›Paper›PMID 30613009›Full record

Trial reportNan fang yi ke da xue xue bao = Journal of Southern Medical University2018

[Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome].

Shunjin Hu, Dong Wang, Rui Zhang, Yuanru Cao, Hua Jin, Yanping Mao, Ling Wei, Kejun Ren, Xuelian Zhang, Yiping Wang

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Shunjin HuFirst Affiliated Hospital, Anhui University of Chinese Medicine, Heifei 230000, China.
Dong WangFirst Affiliated Hospital, Anhui University of Chinese Medicine, Heifei 230000, China.
Rui ZhangGraduate School, Anhui University of Chinese Medicine, Heifei 230000, China.
Yuanru CaoAnhui Provincial Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Hefei 230000, China.
Hua JinFirst Affiliated Hospital, Anhui University of Chinese Medicine, Heifei 230000, China.
Yanping MaoFirst Affiliated Hospital, Anhui University of Chinese Medicine, Heifei 230000, China.
Ling WeiFirst Affiliated Hospital, Anhui University of Chinese Medicine, Heifei 230000, China.
Kejun RenFirst Affiliated Hospital, Anhui University of Chinese Medicine, Heifei 230000, China.
Xuelian ZhangFirst Affiliated Hospital, Anhui University of Chinese Medicine, Heifei 230000, China.
Yiping WangFirst Affiliated Hospital, Anhui University of Chinese Medicine, Heifei 230000, China.
Anhui University of Traditional Chinese Medicine · CNIntegrated Chinese Medicine (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo observe the effect of Ronghuang granule on serum fibroblast growth factor 23 (FGF23), fibroblast growth factor receptor (FGFRs) and Klotho protein levels in non-dialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD) and kidney deficiency and damp heat syndrome.

methodsSeventy non-dialysis CKD-MBD patients with kidney deficiency and dampness-heat syndrome were randomized into control group (

resultsSixty-five patients completed the study, including 33 in the control group and 32 in the treatment group. The patients in the treatment group showed significantly better treatment responses than those in the control group (

conclusionsRonghuang granule improves the clinical symptoms of non-dialysis CKD-MBD patients with kidney deficiency and dampness heat syndrome by reducing serum levels of FGF23, FGFRs and Klotho, improving calcium and phosphorus metabolism disorder, and inhibiting secondary hyperparathyroidism.

Indexed as

CalciumChronic Kidney Disease-Mineral and Bone DisorderDrugs, Chinese HerbalEnemaFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseHumansKlotho ProteinsParathyroid HormonePhosphorusReceptors, Fibroblast Growth FactorRenal Insufficiency, ChronicSweating SicknessSyndromeCalciumDrugs, Chinese HerbalFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseKlotho ProteinsParathyroid HormonePhosphorusReceptors, Fibroblast Growth Factorchronic kidney disease-mineral and bone disorderfibroblast growth factor 23fibroblast growth factor receptorKlotho proteinRonghuang granulesyndrome of kidney deficiency and dampness heat

Identifiers

PMID30613009
PMCPMC6744217
OpenAlexW2912372513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.